The radiosensitizing effect of immunoadjuvant OM-174 requires cooperation between immune and tumor cells through interferon-gamma and inducible nitric oxide synthase

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 5, 2006, Pages 1473-1480

  De Ridder, Mark ^a   Verovski, Valeri N ^a   Chiavaroli, Carlo ^b   Van den Berge, Dirk L ^a   Monsaert, Christinne ^a   Law, Kalun ^a   Storme, Guy A ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b Vifor (International) Inc   (Switzerland)

Author keywords

Hypoxia; Immune cells; Immunoadjuvant OM 174; Interferon gamma; Radiosensitization

Indexed keywords

CELLS; ENZYMES; ONCOLOGY; RADIOTHERAPY; TUMORS;

HYPOXIA; IMMUNE CELLS; IMMUNOADJUVANT OM-174; INTERFERON-GAMMA; RADIOSENSITIZATION;

IMMUNOLOGY;

ANTINEOPLASTIC AGENT; CYTOKINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 18; NEUTRALIZING ANTIBODY; OM 174; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPOXIA; IMMUNOCOMPETENT CELL; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; TUMOR CELL; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME ACTIVATION; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-18; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RADIATION TOLERANCE; RNA, MESSENGER; SPLEEN; UP-REGULATION;

EID: 33751184377     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.07.1381     Document Type: Article

References (52)

1. Poltorak A., He X., Smirnova I., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282 (1998) 2085-2088
2. Engelhardt R., Mackensen A., and Galanos C. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res 51 (1991) 2524-2530
3. Brandenburg K., Lindner B., Schromm A., et al. Physicochemical characteristics of triacyl lipid A partial structure OM-174 in relation to biological activity. Eur J Biochem 267 (2000) 3370-3377
4. de Bono J.S., Dalgleish A.G., Carmichael J., et al. Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res 6 (2000) 397-405
5. Pance A., Reisser D., and Jeannin J.F. Antitumoral effects of lipid A: Preclinical and clinical studies. J Invest Med 50 (2002) 173-178
6. Mattern T., Thanhauser A., Reiling N., et al. Endotoxin and lipid A stimulate proliferation of human T cells in the presence of autologous monocytes. J Immunol 153 (1994) 2996-3004
7. Matsushita K., Kuramitsu Y., Ohiro Y., et al. ONO-4007, a synthetic lipid A analog, induces Th1-type immune response in tumor eradication and restores nitric oxide production by peritoneal macrophages. Int J Oncol 23 (2003) 489-493
8. Thompson B.S., Chilton P.M., Ward J.R., et al. The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J Leukoc Biol 78 (2005) 1273-1280
9. Onier N., Hilpert S., Reveneau S., et al. Expression of inducible nitric oxide synthase in tumors in relation with their regression induced by lipid A in rats. Int J Cancer 81 (1999) 755-760
10. D'Agostini C., Pica F., Febbraro G., et al. Antitumour effect of OM-174 and Cyclophosphamide on murine B16 melanoma in different experimental conditions. Int Immunopharmacol 5 (2005) 1205-1212
11. Janssens M.Y., Van den Berge D.L., Verovski V.N., et al. Activation of inducible nitric oxide synthase results in nitric oxide-mediated radiosensitization of hypoxic EMT-6 tumor cells. Cancer Res 58 (1998) 5646-5648
12. Van den Berge D.L., De Ridder M., Verovski V.N., et al. Chronic hypoxia modulates tumour cell radioresponse through cytokine-inducible nitric oxide synthase. Br J Cancer 84 (2001) 1122-1125
13. Matsuura M., Saito S., Hirai Y., et al. A pathway through interferon-gamma is the main pathway for induction of nitric oxide upon stimulation with bacterial lipopolysaccharide in mouse peritoneal cells. Eur J Biochem 270 (2003) 4016-4025
14. Coughlin C.M., Salhany K.E., Wysocka M., et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 101 (1998) 1441-1452
15. De Ridder M., Verovski V.N., Darville M.I., et al. Macrophages enhance the radiosensitizing activity of lipid A: A novel role for immune cells in tumor cell radioresponse. Int J Radiat Oncol Biol Phys 60 (2004) 598-606
16. Titheradge M.A. The enzymatic measurement of nitrate and nitrite. Methods Mol Biol 100 (1998) 83-91
17. De Ridder M., Verovski V.N., Van den Berge D.L., et al. Lipid a radiosensitizes hypoxic EMT-6 tumor cells: Role of the NF-κB signaling pathway. Int J Radiat Oncol Biol Phys 57 (2003) 779-786
18. De Ridder M., Van den Berge D.L., Verovski V.N., et al. NF-kappaB inhibition impairs the radioresponse of hypoxic EMT-6 tumour cells through downregulation of inducible nitric oxide synthase. Br J Cancer 88 (2003) 120-124
19. Verovski V.N., Van den Berge D.L., Soete G.A., et al. Intrinsic radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside. Br J Cancer 74 (1996) 1734-1742
20. Mitchell J.B., Wink D.A., DeGraff W., et al. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res 53 (1993) 5845-5848
21. Janssens M.Y., Verovski V.N., Van den Berge D.L., et al. Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation. Br J Cancer 79 (1999) 1085-1089
22. Brown J.M., and Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4 (2004) 437-447
23. Puddu P., Fantuzzi L., Borghi P., et al. IL-12 induces IFN-gamma expression and secretion in mouse peritoneal macrophages. J Immunol 159 (1997) 3490-3497
24. Wang J., Wakeham J., Harkness R., et al. Macrophages are a significant source of type 1 cytokines during mycobacterial infection. J Clin Invest 103 (1999) 1023-1029
25. Schleicher U., Hesse A., and Bogdan C. Minute numbers of contaminant CD8+ T cells or CD11b+CD11c+ NK cells are the source of IFN-gamma in IL-12/IL-18-stimulated mouse macrophage populations. Blood 105 (2005) 1319-1328
26. Feng C.G., Jankovic D., Kullberg M., et al. Maintenance of pulmonary Th1 effector function in chronic tuberculosis requires persistent IL-12 production. J Immunol 174 (2005) 4185-4192
27. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 (2003) 133-146
28. Kwak J.Y., Han M.K., Choi K.S., et al. Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells. Cell Immunol 203 (2000) 84-94
29. Melillo G., Taylor L.S., Brooks A., et al. Regulation of inducible nitric oxide synthase expression in IFN-gamma-treated murine macrophages cultured under hypoxic conditions. J Immunol 157 (1996) 2638-2644
30. Xie Q.W., Whisnant R., and Nathan C. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J Exp Med 177 (1993) 1779-1784
31. Wink D.A., Vodovotz Y., Laval J., et al. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19 (1998) 711-721
32. Ambs S., Merriam W.G., Bennett W.P., et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: Implication for tumor angiogenesis and colon cancer progression. Cancer Res 58 (1998) 334-341
33. Thomsen L.L., Miles D.W., Happerfield L., et al. Nitric oxide synthase activity in human breast cancer. Br J Cancer 72 (1995) 41-44
34. Royds J.A., Dower S.K., Qwarnstrom E.E., et al. Response of tumour cells to hypoxia: Role of p53 and NFkB. Mol Pathol 51 (1998) 55-61
35. Bingle L., Brown N.J., and Lewis C.E. The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 196 (2002) 254-265
36. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4 (2004) 71-78
37. Rankin E.B., Yu D., Jiang J., et al. An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth. Cancer Biol Ther 2 (2003) 687-693
38. Nagtegaal I.D., Marijnen C.A., Kranenbarg E.K., et al. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-A histopathological and immunohistochemical study. BMC Cancer 1 (2001) 7
39. Lauerova L., Dusek L., Simickova M., et al. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 49 (2002) 159-166
40. Turk M.J., Guevara-Patino J.A., Rizzuto G.A., et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200 (2004) 771-782
41. Blattman J.N., and Greenberg P.D. Cancer immunotherapy: A treatment for the masses. Science 305 (2004) 200-205
42. de Waal M.R. The role of type I interferons in the differentiation and function of Th1 and Th2 cells. Semin Oncol 24 (1997) S9
43. Demaria S., Ng B., Devitt M.L., et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58 (2004) 862-870
44. Mason K.A., Ariga H., Neal R., et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 11 (2005) 361-369
45. Milas L., Mason K.A., Ariga H., et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 64 (2004) 5074-5077
46. Koski G.K., and Czerniecki B.J. Combining innate immunity with radiation therapy for cancer treatment. Clin Cancer Res 11 (2005) 7-11
47. Demaria S., Bhardwaj N., McBride W.H., et al. Combining radiotherapy and immunotherapy: A revived partnership. Int J Radiat Oncol Biol Phys 63 (2005) 655-666
48. Montrucchio G., Lupia E., De Martino A., et al. Nitric oxide mediates angiogenesis induced in vivo by platelet-activating factor and tumor necrosis factor-alpha. Am J Pathol 151 (1997) 557-563
49. Xie K., Huang S., Dong Z., et al. Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J Natl Cancer Inst 89 (1997) 421-427
50. Hu D.E., Dyke S.O., Moore A.M., et al. Tumor cell-derived nitric oxide is involved in the immune-rejection of an immunogenic murine lymphoma. Cancer Res 64 (2004) 152-161
51. Chinje E.C., Cowen R.L., Feng J., et al. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro. Mol Pharmacol 63 (2003) 1248-1255
52. Shaw E.G., Deming R.L., Creagan E.T., et al. Pilot study of human recombinant interferon gamma and accelerated hyperfractionated thoracic radiation therapy in patients with unresectable Stage IIIA/B non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 31 (1995) 827-831